Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Is a |
Product containing dinoprostone in vaginal dose form (medicinal product form) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Prostaglandin PGE>2< |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Prostaglandin E>1< preparation (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dinoprostone (substance) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Posterior pituitary hormone |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Prostaglandin E1 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has manufactured dose form |
Vaginal dose form |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has manufactured dose form |
Vaginal gel |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has basis of strength substance (attribute) |
Dinoprostone (substance) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has concentration strength denominator value |
un |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has concentration strength numerator unit |
mcg |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has precise active ingredient |
Dinoprostone (substance) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has concentration strength numerator value |
800 |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Count of base of active ingredient |
un |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Has concentration strength denominator unit (attribute) |
Milliliter (qualifier value) |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Is a |
Dinoprostone only product in vaginal dose form |
true |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|
Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
Plays role |
Oxytocic therapeutic role (role) |
false |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
|